Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Japan / NCT06519032
Recruiting Observational

Development and Evaluation of Rapid Bacterial Species Identification for Acid-Fast Bacilli Smear Using Image Analysis AI

NCT06519032 · tracked via the Priya Life Science Japan tracker
Sponsor
GramEye
Phase
Observational
Started
2023-09-20
Last updated
2024-07-26

Condition(s) studied

Bacterial Infections

Study summary

The goal of this observational study is to develop AI that detects and classifies Acid-Fast Bacilli from microscope images using anonymized and fixed glass slides.

Eligibility

Sex
ALL
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Patients in whom acid-fast bacilli(AFB) smear test was ordered Exclusion Criteria: * No exclusion criteria

Primary outcome measure(s)

  • Rate of concordance between AI-estimated results with actual culture results regarding the presence or absence of acid-fast bacteria — Day1
    Evaluate the difference between actual medical record reports(such as culture results) and AI-estimated results regarding the presence or absence of acid-fast bacteria

Trial sites (1)

FacilityCityRegionStatus
Osaka University Hospital Suita Osaka Recruiting

More GramEye trials in Japan

Development and Evaluation of AI Program for Predicting Bacterial Species From Urine Gram Stain Specimens Recruiting
Development and Accuracy Evaluation of Gram Staining Analysis AI Recruiting

Other trials for the same condition

Development and Evaluation of AI Program for Predicting Bacterial Species From Urine Gram Stain Specimens Recruiting
Development and Accuracy Evaluation of Gram Staining Analysis AI Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06519032 on ClinicalTrials.gov ↗ ← All trials in Japan